| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Mónika Szűcs, Róbert Kui, Rolland Gyulai, Anita Bálint, Tibor Wittmann and Tamás Molnár |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| TAMOP-4.2.2.A-11/1/KONV |
2012-0035 |
| TAMOP-4.2.2-A-11/1/KONV |
2012-0052 |
| TAMOP-4.2.2.A-11/1/KONV |
2012-0073 |
| OTKA Research Proposal PD |
105948 |
|
| Corresponding Author |
amás Molnár, MD, PhD, First Department of Medicine, University of Szeged, Korányi fasor 8-10, H6720 Szeged, Hungary. molnar.tamas@med.u-szeged.hu |
| Key Words |
Tumor necrosis factor-α; Infliximab; Antibody; Inflammatory bowel disease |
| Core Tip |
The clinical utility of measuring serum tumor necrosis factor-α (TNF-α), infliximab, and anti-infliximab levels in the therapeutic decisions of patients with inflammatory bowel disease is still an outstanding question. In this study we assessed TNF-α, infliximab concentrations, and antibodies against infliximab molecules in patients with inflammatory bowel disease who developed loss of response, side effects, or allergic reaction during anti TNF-α therapy. Our results showed that the simultaneous measurement of serum TNF-α level, serum anti TNF-α concentration, and antibodies against anti TNF-α may further help to optimize therapy in critical situations. |
| Publish Date |
2014-05-07 10:10 |
| Citation |
Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i17/5031.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i17.5031 |
